theophylline has been researched along with Disease Exacerbation in 20 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " The current experiment has tested the hypothesis that green tea and the methylxanthine theophylline contained in tea inhibit the progression of neuroendocrine lung carcinogenesis in hamsters with hyperoxic lung injury and initiated with the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) while promoting the development of Clara cell-derived pulmonary adenocarcinomas initiated by NNK in healthy hamsters." | 7.72 | Neuroendocrine lung carcinogenesis in hamsters is inhibited by green tea or theophylline while the development of adenocarcinomas is promoted: implications for chemoprevention in smokers. ( Porter, B; Riechert, A; Schmoyer, R; Schuller, HM; Walker, K, 2004) |
| "Chronic obstructive pulmonary disease (COPD) has become a global epidemic disease with an increased morbidity and mortality in the world." | 6.48 | Can β2-adrenoceptor agonists, anticholinergic drugs, and theophylline contribute to the control of pulmonary inflammation and emphysema in COPD? ( Advenier, C; Bureau, F; Cambier, C; Cui, YY; Devillier, P; Gustin, P; Rong, WF; Zhang, WH; Zhang, Y, 2012) |
| "We used a secondary observational analysis of pregnant women with mild and moderate-severe asthma enrolled in a prospective observational cohort study of asthma in pregnancy and a randomized clinical trial (RCT) comparing inhaled beclomethasone and oral theophylline." | 5.14 | The effect of active and passive household cigarette smoke exposure on pregnant women with asthma. ( Caritis, SN; Conway, DL; Dombrowski, MP; Landon, M; Lindheimer, M; Miodovnik, M; Momirova, V; Newman, RB; O'Sullivan, MJ; Rouse, DJ; Schatz, M; Sheffield, J; Varner, MW; Wapner, RJ; Wise, R, 2010) |
| " Obese and non-obese subjects with asthma had similar airflow limitation and bronchodilator responsiveness, but obese participants had increased sleep disturbance and gastroesophageal reflux disease, higher cytokine levels, and a trend towards increased exacerbations when treated with theophylline." | 5.12 | Effect of obesity on clinical presentation and response to treatment in asthma. ( Allayee, H; Cohen, RI; Dixon, AE; Holbrook, JT; Irvin, CG; Lima, JJ; Shade, DM; Skloot, GS; Smith, LJ; Wise, RA, 2006) |
| "We show that cyclic AMP (cAMP) elevating agents protect blasts from patients with acute promyelocytic leukemia (APL) against death induced by first-line anti-leukemic anthracyclines like daunorubicin (DNR)." | 3.79 | Cyclic AMP can promote APL progression and protect myeloid leukemia cells against anthracycline-induced apoptosis. ( Bruserud, O; Døskeland, SO; Gausdal, G; Gjertsen, BT; Havemann, U; Herfindal, L; Kleppe, R; Lanotte, M; McCormack, E; Nguyen, E; Pendino, F; Rouhee, N; Schwede, F; Ségal-Bendirdjian, E; Skavland, J; Wergeland, A, 2013) |
| " The current experiment has tested the hypothesis that green tea and the methylxanthine theophylline contained in tea inhibit the progression of neuroendocrine lung carcinogenesis in hamsters with hyperoxic lung injury and initiated with the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) while promoting the development of Clara cell-derived pulmonary adenocarcinomas initiated by NNK in healthy hamsters." | 3.72 | Neuroendocrine lung carcinogenesis in hamsters is inhibited by green tea or theophylline while the development of adenocarcinomas is promoted: implications for chemoprevention in smokers. ( Porter, B; Riechert, A; Schmoyer, R; Schuller, HM; Walker, K, 2004) |
| " In vitro studies of human chronic lymphocytic leukemia cells incubated with theophylline, a phosphodiesterase inhibitor, resulted in downregulation of bcl-2 concomitant with induction of apoptosis." | 3.70 | Theophylline, pentostatin (Nipent), and chlorambucil: a dose-escalation study targeting intrinsic biologic resistance mechanisms in patients with relapsed lymphoproliferative disorders. ( Byrd, JC; Flinn, IW; Goodrich, A; Grever, MR; Lucas, MA; Park, K; Shinn, C; Waselenko, JK; Willis, CR, 2000) |
| " Dosing is based on pharmacokinetic modelling to achieve a steady-state serum theophylline of 1-5 mg/l." | 2.80 | Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial. ( Barnes, P; Briggs, A; Burns, G; Chaudhuri, R; Chrystyn, H; Cotton, S; Davies, L; De Soyza, A; Devereux, G; Fielding, S; Gompertz, S; Haughney, J; Lee, AJ; McCormack, K; McPherson, G; Morice, A; Norrie, J; Price, D; Sullivan, A; Wilson, A, 2015) |
| "In patients with COPD who are not on maintenance therapy, tiotropium is associated with significant benefits in disease progression." | 2.75 | Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. ( Celli, B; Decramer, M; Kesten, S; Lystig, T; Mehra, S; Tashkin, DP; Troosters, T, 2010) |
| "Chronic obstructive pulmonary disease (COPD) has become a global epidemic disease with an increased morbidity and mortality in the world." | 2.48 | Can β2-adrenoceptor agonists, anticholinergic drugs, and theophylline contribute to the control of pulmonary inflammation and emphysema in COPD? ( Advenier, C; Bureau, F; Cambier, C; Cui, YY; Devillier, P; Gustin, P; Rong, WF; Zhang, WH; Zhang, Y, 2012) |
| "Theophylline has weak antiinflammatory effects." | 2.42 | [New drug therapy of chronic obstructive pulmonary disease]. ( Kino, H, 2003) |
| "The Spanish COPD Guidelines (GesEPOC) is an initiative of SEPAR, which, together with the scientific societies involved in COPD patient care, and the Spanish Patient Forum, has developed these new clinical practice guidelines." | 1.38 | Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery. ( Almagro, P; Ancochea, J; Calle, M; López-Campos, JL; Miravitlles, M; Molina, J; Piñera, P; Quintano, JA; Riesco, JA; Simón, A; Soler-Cataluña, JJ; Soriano, JB; Trigueros, JA, 2012) |
| "Despite increased awareness, COPD remains underdiagnosed." | 1.36 | [Update on current care guidelines: Chronic obstructive pulmonary disease, diagnosis and treatment]. ( , 2010) |
| " All patients received inhaled corticosteroids; only 44 had high dosed corticosteroids." | 1.33 | [Treatment compliance in asthma: a Tunisian transversal study]. ( Ali, BK; Ikram, D; Radhouane, F; Sonia, M, 2005) |
| "Exacerbations in COPD patients are characterized by an acute aggravation of the condition with an increase in symptoms (labored breathing, cough, expectoration, tightness of the chest and, rarely, fever)." | 1.33 | [COPD--how to deal with an acute exacerbation]. ( Worth, H, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.00) | 18.2507 |
| 2000's | 6 (30.00) | 29.6817 |
| 2010's | 11 (55.00) | 24.3611 |
| 2020's | 2 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sevik, OE | 1 |
| Canakci, ME | 1 |
| Matheny, M | 1 |
| Maleque, N | 1 |
| Channell, N | 1 |
| Eisch, AR | 1 |
| Auld, SC | 1 |
| Banerji, A | 1 |
| Druey, KM | 1 |
| Matera, MG | 1 |
| Page, C | 1 |
| Cazzola, M | 1 |
| Gausdal, G | 1 |
| Wergeland, A | 1 |
| Skavland, J | 1 |
| Nguyen, E | 1 |
| Pendino, F | 1 |
| Rouhee, N | 1 |
| McCormack, E | 1 |
| Herfindal, L | 1 |
| Kleppe, R | 1 |
| Havemann, U | 1 |
| Schwede, F | 1 |
| Bruserud, O | 1 |
| Gjertsen, BT | 1 |
| Lanotte, M | 1 |
| Ségal-Bendirdjian, E | 1 |
| Døskeland, SO | 1 |
| Kirkham, PA | 1 |
| Whiteman, M | 1 |
| Winyard, PG | 1 |
| Caramori, G | 1 |
| Gordon, F | 1 |
| Ford, PA | 1 |
| Barnes, PJ | 1 |
| Adcock, IM | 1 |
| Chung, KF | 1 |
| Tsuchida, T | 1 |
| Matsuse, H | 1 |
| Costanzo, MR | 1 |
| Khayat, R | 1 |
| Ponikowski, P | 1 |
| Augostini, R | 1 |
| Stellbrink, C | 1 |
| Mianulli, M | 1 |
| Abraham, WT | 1 |
| Devereux, G | 1 |
| Cotton, S | 1 |
| Barnes, P | 1 |
| Briggs, A | 1 |
| Burns, G | 1 |
| Chaudhuri, R | 1 |
| Chrystyn, H | 1 |
| Davies, L | 1 |
| De Soyza, A | 1 |
| Fielding, S | 1 |
| Gompertz, S | 1 |
| Haughney, J | 1 |
| Lee, AJ | 1 |
| McCormack, K | 1 |
| McPherson, G | 1 |
| Morice, A | 1 |
| Norrie, J | 1 |
| Sullivan, A | 1 |
| Wilson, A | 1 |
| Price, D | 1 |
| Newman, RB | 1 |
| Momirova, V | 1 |
| Dombrowski, MP | 1 |
| Schatz, M | 1 |
| Wise, R | 1 |
| Landon, M | 1 |
| Rouse, DJ | 1 |
| Lindheimer, M | 1 |
| Caritis, SN | 1 |
| Sheffield, J | 1 |
| Miodovnik, M | 1 |
| Wapner, RJ | 1 |
| Varner, MW | 1 |
| O'Sullivan, MJ | 1 |
| Conway, DL | 1 |
| Troosters, T | 1 |
| Celli, B | 1 |
| Lystig, T | 1 |
| Kesten, S | 1 |
| Mehra, S | 1 |
| Tashkin, DP | 1 |
| Decramer, M | 1 |
| Zhang, WH | 1 |
| Zhang, Y | 1 |
| Cui, YY | 1 |
| Rong, WF | 1 |
| Cambier, C | 1 |
| Devillier, P | 1 |
| Bureau, F | 1 |
| Advenier, C | 1 |
| Gustin, P | 1 |
| Miravitlles, M | 1 |
| Soler-Cataluña, JJ | 1 |
| Calle, M | 1 |
| Molina, J | 1 |
| Almagro, P | 1 |
| Quintano, JA | 1 |
| Riesco, JA | 1 |
| Trigueros, JA | 1 |
| Piñera, P | 1 |
| Simón, A | 1 |
| López-Campos, JL | 1 |
| Soriano, JB | 1 |
| Ancochea, J | 1 |
| Kino, H | 1 |
| Schuller, HM | 1 |
| Porter, B | 1 |
| Riechert, A | 1 |
| Walker, K | 1 |
| Schmoyer, R | 1 |
| Sonia, M | 1 |
| Ikram, D | 1 |
| Radhouane, F | 1 |
| Ali, BK | 1 |
| Worth, H | 1 |
| Dixon, AE | 1 |
| Shade, DM | 1 |
| Cohen, RI | 1 |
| Skloot, GS | 1 |
| Holbrook, JT | 1 |
| Smith, LJ | 1 |
| Lima, JJ | 1 |
| Allayee, H | 1 |
| Irvin, CG | 1 |
| Wise, RA | 1 |
| Yamada, K | 1 |
| Kida, K | 1 |
| Byrd, JC | 1 |
| Grever, MR | 1 |
| Waselenko, JK | 1 |
| Willis, CR | 1 |
| Park, K | 1 |
| Goodrich, A | 1 |
| Lucas, MA | 1 |
| Shinn, C | 1 |
| Flinn, IW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Enhancement of In-vitro GC Function in Patients With COPD. A Randomised, Double Blind, Placebo Controlled, Parallel-group Study to Investigate the Effect of Theophylline and Fluticasone on Induced Sputum Cells Obtained Form COPD Patients[NCT00241631] | Phase 2 | 49 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial Assessing the Rate of Decline of Lung Function With Tiotropium 18 mcg Inhalation Capsule Once Daily in Patients With Chronic Obstructive Pulmonary Disease (COPD).[NCT00144339] | Phase 3 | 5,993 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Interleukin 8 (IL8) assessed from sputum (NCT00241631)
Timeframe: 10 weeks
| Intervention | ng/mL (Mean) |
|---|---|
| Placebo | 33.3 |
| Steroid | 28.3 |
Supernatant collect, cell pellets count on slides (NCT00241631)
Timeframe: 10 weeks
| Intervention | millions cells/ ml (Mean) |
|---|---|
| Placebo | 5.42 |
| Steroid | 3.89 |
Total eosinophils cells assessed from sputum (NCT00241631)
Timeframe: 10 weeks
| Intervention | millions cells/ml (Mean) |
|---|---|
| Placebo | 0.132 |
| Steroid | 0.053 |
Number of days with chronic obstructive pulmonary disease (COPD) exacerbation leading to hospitalization (normalized by treatment exposure) (NCT00144339)
Timeframe: From Day 1 to 4 years
| Intervention | days/patient year (Mean) |
|---|---|
| Placebo | 3.13 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 3.17 |
Estimated forced expiratory volume in one second (FEV1) after bronchodilator at month 1 (NCT00144339)
Timeframe: Month 1
| Intervention | L (Mean) |
|---|---|
| Placebo | 1.372 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 1.418 |
(NCT00144339)
Timeframe: Month 12
| Intervention | L (Mean) |
|---|---|
| Placebo | 1.345 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 1.398 |
(NCT00144339)
Timeframe: Month 18
| Intervention | L (Mean) |
|---|---|
| Placebo | 1.326 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 1.379 |
(NCT00144339)
Timeframe: Month 24
| Intervention | L (Mean) |
|---|---|
| Placebo | 1.294 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 1.356 |
(NCT00144339)
Timeframe: Month 30
| Intervention | L (Mean) |
|---|---|
| Placebo | 1.274 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 1.335 |
(NCT00144339)
Timeframe: Month 36
| Intervention | L (Mean) |
|---|---|
| Placebo | 1.250 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 1.315 |
Estimated FEV1 after bronchodilator at Month 42 (NCT00144339)
Timeframe: Month 42
| Intervention | L (Mean) |
|---|---|
| Placebo | 1.236 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 1.297 |
(NCT00144339)
Timeframe: Month 48
| Intervention | L (Mean) |
|---|---|
| Placebo | 1.219 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 1.268 |
(NCT00144339)
Timeframe: Month 6
| Intervention | L (Mean) |
|---|---|
| Placebo | 1.365 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 1.423 |
(NCT00144339)
Timeframe: Month 1
| Intervention | L (Mean) |
|---|---|
| Placebo | 3.149 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 3.204 |
(NCT00144339)
Timeframe: Month 12
| Intervention | L (Mean) |
|---|---|
| Placebo | 3.110 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 3.158 |
(NCT00144339)
Timeframe: Month 18
| Intervention | L (Mean) |
|---|---|
| Placebo | 3.075 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 3.126 |
(NCT00144339)
Timeframe: Month 24
| Intervention | L (Mean) |
|---|---|
| Placebo | 3.036 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 3.095 |
(NCT00144339)
Timeframe: Month 30
| Intervention | L (Mean) |
|---|---|
| Placebo | 3.010 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 3.057 |
(NCT00144339)
Timeframe: Month 36
| Intervention | L (Mean) |
|---|---|
| Placebo | 2.973 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 3.038 |
(NCT00144339)
Timeframe: Month 42
| Intervention | L (Mean) |
|---|---|
| Placebo | 2.959 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 3.005 |
(NCT00144339)
Timeframe: Month 48
| Intervention | L (Mean) |
|---|---|
| Placebo | 2.929 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 2.961 |
(NCT00144339)
Timeframe: Month 6
| Intervention | L (Mean) |
|---|---|
| Placebo | 3.137 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 3.193 |
(NCT00144339)
Timeframe: Month 1
| Intervention | L (Mean) |
|---|---|
| Placebo | 3.280 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 3.318 |
(NCT00144339)
Timeframe: Month 12
| Intervention | L (Mean) |
|---|---|
| Placebo | 3.228 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 3.260 |
(NCT00144339)
Timeframe: Month 18
| Intervention | L (Mean) |
|---|---|
| Placebo | 3.195 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 3.234 |
(NCT00144339)
Timeframe: Month 24
| Intervention | L (Mean) |
|---|---|
| Placebo | 3.157 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 3.189 |
(NCT00144339)
Timeframe: Month 30
| Intervention | L (Mean) |
|---|---|
| Placebo | 3.126 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 3.157 |
(NCT00144339)
Timeframe: Month 36
| Intervention | L (Mean) |
|---|---|
| Placebo | 3.086 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 3.136 |
(NCT00144339)
Timeframe: Month 42
| Intervention | L (Mean) |
|---|---|
| Placebo | 3.073 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 3.100 |
(NCT00144339)
Timeframe: Month 48
| Intervention | L (Mean) |
|---|---|
| Placebo | 3.041 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 3.067 |
(NCT00144339)
Timeframe: Month 6
| Intervention | L (Mean) |
|---|---|
| Placebo | 3.268 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 3.304 |
Estimated FEV1 before bronchodilator at Month 1 (NCT00144339)
Timeframe: Month 1
| Intervention | L (Mean) |
|---|---|
| Placebo | 1.134 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 1.221 |
(NCT00144339)
Timeframe: Month 12
| Intervention | L (Mean) |
|---|---|
| Placebo | 1.111 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 1.213 |
(NCT00144339)
Timeframe: Month 18
| Intervention | L (Mean) |
|---|---|
| Placebo | 1.101 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 1.192 |
(NCT00144339)
Timeframe: Month 24
| Intervention | L (Mean) |
|---|---|
| Placebo | 1.079 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 1.173 |
(NCT00144339)
Timeframe: Month 30
| Intervention | L (Mean) |
|---|---|
| Placebo | 1.061 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 1.156 |
(NCT00144339)
Timeframe: Month 36
| Intervention | L (Mean) |
|---|---|
| Placebo | 1.045 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 1.144 |
(NCT00144339)
Timeframe: Month 42
| Intervention | L (Mean) |
|---|---|
| Placebo | 1.034 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 1.129 |
(NCT00144339)
Timeframe: Month 48
| Intervention | L (Mean) |
|---|---|
| Placebo | 1.024 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 1.112 |
Estimated forced expiratory volume in one second (FEV1) before bronchodilator at month 6 (NCT00144339)
Timeframe: Month 6
| Intervention | L (Mean) |
|---|---|
| Placebo | 1.126 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 1.225 |
(NCT00144339)
Timeframe: Month 1
| Intervention | L (Mean) |
|---|---|
| Placebo | 2.667 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 2.856 |
(NCT00144339)
Timeframe: Month 12
| Intervention | L (Mean) |
|---|---|
| Placebo | 2.640 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 2.838 |
(NCT00144339)
Timeframe: Month 18
| Intervention | L (Mean) |
|---|---|
| Placebo | 2.622 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 2.816 |
(NCT00144339)
Timeframe: Month 24
| Intervention | L (Mean) |
|---|---|
| Placebo | 2.597 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 2.785 |
(NCT00144339)
Timeframe: Month 30
| Intervention | L (Mean) |
|---|---|
| Placebo | 2.572 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 2.757 |
(NCT00144339)
Timeframe: Month 36
| Intervention | L (Mean) |
|---|---|
| Placebo | 2.553 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 2.753 |
(NCT00144339)
Timeframe: Month 42
| Intervention | L (Mean) |
|---|---|
| Placebo | 2.540 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 2.724 |
(NCT00144339)
Timeframe: Month 48
| Intervention | L (Mean) |
|---|---|
| Placebo | 2.532 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 2.702 |
(NCT00144339)
Timeframe: Month 6
| Intervention | L (Mean) |
|---|---|
| Placebo | 2.658 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 2.862 |
(NCT00144339)
Timeframe: Month 1
| Intervention | L (Mean) |
|---|---|
| Placebo | 2.847 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 3.017 |
(NCT00144339)
Timeframe: Month 12
| Intervention | L (Mean) |
|---|---|
| Placebo | 2.820 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 2.996 |
(NCT00144339)
Timeframe: Month 18
| Intervention | L (Mean) |
|---|---|
| Placebo | 2.811 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 2.965 |
(NCT00144339)
Timeframe: Month 24
| Intervention | L (Mean) |
|---|---|
| Placebo | 2.775 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 2.942 |
(NCT00144339)
Timeframe: Month 30
| Intervention | L (Mean) |
|---|---|
| Placebo | 2.738 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 2.908 |
(NCT00144339)
Timeframe: Month 36
| Intervention | L (Mean) |
|---|---|
| Placebo | 2.731 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 2.897 |
(NCT00144339)
Timeframe: Month 42
| Intervention | L (Mean) |
|---|---|
| Placebo | 2.713 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 2.875 |
(NCT00144339)
Timeframe: Month 48
| Intervention | L (Mean) |
|---|---|
| Placebo | 2.696 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 2.846 |
(NCT00144339)
Timeframe: Month 6
| Intervention | L (Mean) |
|---|---|
| Placebo | 2.841 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 3.027 |
"SGRQ total score summarizes the impact of COPD on overall patient's health status.~Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.~The scale is continuous.~Rate of decline shows the yearly change of SGRQ total score." (NCT00144339)
Timeframe: Month 12
| Intervention | Units on a scale (Mean) |
|---|---|
| Placebo | 42.501 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 39.730 |
"SGRQ total score summarizes the impact of COPD on overall patient's health status.~Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.~The scale is continuous.~Rate of decline shows the yearly change of SGRQ total score." (NCT00144339)
Timeframe: Month 18
| Intervention | Units on a scale (Mean) |
|---|---|
| Placebo | 43.067 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 40.474 |
"SGRQ total score summarizes the impact of COPD on overall patient's health status.~Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.~The scale is continuous.~Rate of decline shows the yearly change of SGRQ total score." (NCT00144339)
Timeframe: Month 24
| Intervention | Units on a scale (Mean) |
|---|---|
| Placebo | 43.562 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 41.178 |
"SGRQ total score summarizes the impact of COPD on overall patient's health status.~Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.~The scale is continuous.~Rate of decline shows the yearly change of SGRQ total score." (NCT00144339)
Timeframe: Month 30
| Intervention | Units on a scale (Mean) |
|---|---|
| Placebo | 44.342 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 41.919 |
"SGRQ total score summarizes the impact of COPD on overall patient's health status.~Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.~The scale is continuous.~Rate of decline shows the yearly change of SGRQ total score." (NCT00144339)
Timeframe: Month 36
| Intervention | Units on a scale (Mean) |
|---|---|
| Placebo | 45.280 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 41.935 |
"SGRQ total score summarizes the impact of COPD on overall patient's health status.~Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.~The scale is continuous.~Rate of decline shows the yearly change of SGRQ total score." (NCT00144339)
Timeframe: Month 42
| Intervention | Units on a scale (Mean) |
|---|---|
| Placebo | 45.722 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 42.905 |
"SGRQ total score summarizes the impact of COPD on overall patient's health status.~Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.~The scale is continuous.~Rate of decline shows the yearly change of SGRQ total score." (NCT00144339)
Timeframe: Month 48
| Intervention | Units on a scale (Mean) |
|---|---|
| Placebo | 45.968 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 43.665 |
"SGRQ total score summarizes the impact of COPD on overall patient's health status.~Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.~The scale is continuous.~Rate of decline shows the yearly change of SGRQ total score." (NCT00144339)
Timeframe: Month 6
| Intervention | Units on a scale (Mean) |
|---|---|
| Placebo | 42.289 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 39.409 |
(NCT00144339)
Timeframe: Day 1 to 4 years
| Intervention | number per patient year (Mean) |
|---|---|
| Placebo | 0.85 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 0.73 |
Number of exacerbation days normalized by treatment exposure (NCT00144339)
Timeframe: Day 1 to 4 years
| Intervention | days/patient year (Mean) |
|---|---|
| Placebo | 13.64 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 12.11 |
Estimated number of exacerbations leading to hospitalizations per patient year (NCT00144339)
Timeframe: From Day 1 to 4 years
| Intervention | Number per patient year (Number) |
|---|---|
| Placebo | 0.16 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 0.15 |
Rate of decline of forced expiratory volume in one second (FEV1) measured after the use of bronchodilators. A negative rate of decline indicates decreasing FEV1 over time, while a positive value indicates increasing FEV1 (NCT00144339)
Timeframe: Day 1 to 30 days after completion of double blinded treatment between Day 1 and 4 years plus 30 days
| Intervention | ml/year (Median) |
|---|---|
| Placebo | -32 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | -27 |
Rate of decline of forced expiratory volume in one second (FEV1) measured after bronchodilation. A negative rate of decline indicates decreasing FEV1 over time, while a positive value indicates increasing FEV1. (NCT00144339)
Timeframe: From day 30 to 4 years
| Intervention | ml/year (Mean) |
|---|---|
| Placebo | -42 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | -40 |
Rate of decline of forced vital capacity (FVC) after bronchodilation. A negative rate of decline indicates decreasing FVC over time, while a positive value indicates increasing FVC (NCT00144339)
Timeframe: Day 1 to 30 days after completion of double blinded treatment between Day 1 and 4 years plus 30 days
| Intervention | ml/year (Median) |
|---|---|
| Placebo | -40 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | -40 |
Rate of decline of forced vital capacity (FVC) measured after bronchodilation. A negative rate of decline indicates decreasing FVC over time, while a positive value indicates increasing FVC (NCT00144339)
Timeframe: From day 30 to 4 years
| Intervention | ml/year (Mean) |
|---|---|
| Placebo | -61 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | -61 |
Rate of decline of slow vital capacity (SVC) after bronchodilation. A negative rate of decline indicates decreasing SVC over time, while a positive value indicates increasing SVC (NCT00144339)
Timeframe: Day 1 to 30 days after completion of double blinded treatment between Day 1 and 4 years plus 30 days
| Intervention | ml/year (Median) |
|---|---|
| Placebo | -46 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | -42 |
Rate of decline of slow vital capacity (SVC) measured after bronchodilation. A negative rate of decline indicates decreasing SVC over time, while a positive value indicates increasing SVC (NCT00144339)
Timeframe: From day 30 to 4 years
| Intervention | ml/year (Mean) |
|---|---|
| Placebo | -65 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | -66 |
Rate of decline of forced expiratory volume in one second (FEV1) measured before the use of bronchodilators. A negative rate of decline indicates decreasing FEV1 over time, while a positive value indicates increasing FEV1 (NCT00144339)
Timeframe: Day 1 to 30 days after completion of double blinded treatment between Day 1 and 4 years plus 30 days.
| Intervention | ml/year (Median) |
|---|---|
| Placebo | -17 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | -15 |
Rate of decline of forced expiratory volume in one second (FEV1) measured before the use of bronchodilators. A negative rate of decline indicates decreasing FEV1 over time, while a positive value indicates increasing FEV1. (NCT00144339)
Timeframe: From day 30 to 4 years
| Intervention | ml/year (Mean) |
|---|---|
| Placebo | -30 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | -30 |
Rate of decline of forced vital capacity (FVC) before bronchodilation. A negative rate of decline indicates decreasing FVC over time, while a positive value indicates increasing FVC (NCT00144339)
Timeframe: Day 1 to 30 days after completion of double blinded treatment between Day 1 and 4 years plus 30 days.
| Intervention | ml/year (Median) |
|---|---|
| Placebo | -12 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | -10 |
Rate of decline of forced vital capacity (FVC) measured before the use of bronchodilators. A negative rate of decline indicates decreasing FVC over time, while a positive value indicates increasing FVC (NCT00144339)
Timeframe: From day 30 to 4 years
| Intervention | ml/year (Mean) |
|---|---|
| Placebo | -39 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | -43 |
Rate of decline slow vital capacity (SVC) before bronchodilation. A negative rate of decline indicates decreasing SVC over time, while a positive value indicates increasing SVC (NCT00144339)
Timeframe: Day 1 to 30 days after completion of double blinded treatment between Day 1 and 4 years plus 30 days
| Intervention | ml/year (Median) |
|---|---|
| Placebo | -17 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | -17 |
Rate of decline of slow vital capacity (SVC) measured before the use of bronchodilators. A negative rate of decline indicates decreasing SVC over time, while a positive value indicates increasing SVC (NCT00144339)
Timeframe: From day 30 to 4 years
| Intervention | ml/year (Mean) |
|---|---|
| Placebo | -41 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | -47 |
SGRQ total score shows the impact of COPD on patient's health status, and expressed as a percentage of impairment with scale from 0 (best health status) to 100 (worst possible status). A negative rate of decline shows decreasing SGRQ total score (or improved health) over time, while a positive value shows increasing score (or worsen health). (NCT00144339)
Timeframe: From month 6 to 4 years
| Intervention | Score on scale per year (Mean) |
|---|---|
| Placebo | 1.21 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 1.25 |
(NCT00144339)
Timeframe: Day 1 to 4 years
| Intervention | months (Median) |
|---|---|
| Placebo | 28.64 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 35.89 |
Chronic obstructive pulmonary disease (COPD) exacerbation (NCT00144339)
Timeframe: From Day 1 to 4 years
| Intervention | months (Median) |
|---|---|
| Placebo | 12.51 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 16.65 |
Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100. (NCT00144339)
Timeframe: Day 1 to completion of double blinded treatment plus 30 days
| Intervention | Number of patients with event (Number) | |
|---|---|---|
| Number of patients with event | Incidence rate (number events/100-patient years) | |
| Placebo | 31 | 0.36 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 48 | 0.51 |
Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100. (NCT00144339)
Timeframe: Day 1 to completion of double blinded treatment plus 30 days
| Intervention | Number of patients with event (Number) | |
|---|---|---|
| Number of patients with event | Incidence rate (number events/100-patient years) | |
| Placebo | 67 | 0.77 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 69 | 0.74 |
Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100. (NCT00144339)
Timeframe: Day 1 to completion of double blinded treatment plus 30 days
| Intervention | Number of patients with event (Number) | |
|---|---|---|
| Number of patients with event | Incidence rate (number events/100-patient years) | |
| Placebo | 27 | 0.31 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 35 | 0.37 |
Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100. (NCT00144339)
Timeframe: Day 1 to completion of double blinded treatment plus 30 days
| Intervention | Number of patients with event (Number) | |
|---|---|---|
| Number of patients with event | Incidence rate (number events/100-patient years) | |
| Placebo | 42 | 0.48 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 27 | 0.29 |
Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100. (NCT00144339)
Timeframe: Day 1 to completion of double blinded treatment plus 30 days
| Intervention | Number of patients with event (Number) | |
|---|---|---|
| Number of patients with event | Incidence rate (number events/100-patient years) | |
| Placebo | 42 | 0.48 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 57 | 0.61 |
Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100. (NCT00144339)
Timeframe: Day 1 to completion of double blinded treatment plus 30 days
| Intervention | Number of patients with event (Number) | |
|---|---|---|
| Number of patients with event | Incidence rate (number events/100-patient years) | |
| Placebo | 742 | 9.70 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 688 | 8.19 |
Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100. (NCT00144339)
Timeframe: Day 1 to completion of double blinded treatment plus 30 days
| Intervention | Number of patients with event (Number) | |
|---|---|---|
| Number of patients with event | Incidence rate (number events/100-patient years) | |
| Placebo | 32 | 0.37 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 20 | 0.21 |
Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100. (NCT00144339)
Timeframe: Day 1 to completion of double blinded treatment plus 30 days
| Intervention | Number of patients with event (Number) | |
|---|---|---|
| Number of patients with event | Incidence rate (number events/100-patient years) | |
| Placebo | 54 | 0.62 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 36 | 0.38 |
Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100. (NCT00144339)
Timeframe: Day 1 to completion of double blinded treatment plus 30 days
| Intervention | Number of patients with event (Number) | |
|---|---|---|
| Number of patients with event | Incidence rate (number events/100-patient years) | |
| Placebo | 84 | 0.97 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 65 | 0.69 |
Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100. (NCT00144339)
Timeframe: Day 1 to completion of double blinded treatment plus 30 days
| Intervention | Number of patients with event (Number) | |
|---|---|---|
| Number of patients with event | Incidence rate (number events/100-patient years) | |
| Placebo | 290 | 3.46 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 296 | 3.28 |
Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100. (NCT00144339)
Timeframe: Day 1 to completion of double blinded treatment plus 30 days
| Intervention | Number of patients with event (Number) | |
|---|---|---|
| Number of patients with event | Incidence rate (number events/100-patient years) | |
| Placebo | 113 | 1.31 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 85 | 0.90 |
Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100. (NCT00144339)
Timeframe: Day 1 to completion of double blinded treatment plus 30 days
| Intervention | Number of patients with event (Number) | |
|---|---|---|
| Number of patients with event | Incidence rate (number of events/100 patient year) | |
| Placebo | 350 | 4.21 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 322 | 3.56 |
Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100. (NCT00144339)
Timeframe: Day 1 to completion of double blinded treatment plus 30 days
| Intervention | Number of patients with event (Number) | |
|---|---|---|
| Number of patients with event | Incidence rate (number events/100-patient years) | |
| Placebo | 985 | 13.47 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 911 | 11.32 |
The primary cause of death was adjudicated by an external committee prior to unblinding; vital status was information followed-up after discontinuation; vital status information up to 1470 days after the start of treatment was used (NCT00144339)
Timeframe: Day 1 to day 1470
| Intervention | Participants (Number) | |
|---|---|---|
| Number of patients with lower respiratory death | Percentage patients with lower respiratory death | |
| Placebo | 173 | 5.8 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 153 | 5.1 |
(NCT00144339)
Timeframe: Day 1 to day 1440
| Intervention | Participants (Number) | |
|---|---|---|
| Number of patients died from day 1 to day 1440 | Percentage of patients died from day 1 to day 1440 | |
| Placebo | 491 | 16.3 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 430 | 14.4 |
All cause mortality vital status information was followed-up after discontinuation; vital status information up to 1470 days after the start of treatment was used. (NCT00144339)
Timeframe: Day 1 to day 1470
| Intervention | Participants (Number) | |
|---|---|---|
| Number of patients died from day 1 to day 1470 | Percentage of patients died from day 1 to day 1470 | |
| Placebo | 495 | 16.5 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 446 | 14.9 |
On-treatment defined as day 1 to completion of double blinded treatment plus 30 days (NCT00144339)
Timeframe: Day 1 to completion of double blinded treatment plus 30 days between Day 1 and 4 years plus 30 days
| Intervention | Participants (Number) | |
|---|---|---|
| Number of patients with on-treatment death | Percentage patients with on-treatment death | |
| Placebo | 402 | 13.4 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 374 | 12.5 |
The primary cause of death was adjudicated by an external committee prior to unblinding; on-treatment defined as day 1 to completion of double blinded treatment plus 30 days (NCT00144339)
Timeframe: Day 1 to completion of double blinded treatment plus 30 days between Day 1 and 4 years plus 30 days
| Intervention | Participants (Number) | |
|---|---|---|
| Number of patients with lower respiratory | Percentage of patients with lower respiratory | |
| Placebo | 140 | 4.7 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 131 | 4.4 |
(NCT00144339)
Timeframe: From Day 1 to 4 years
| Intervention | Participants (Number) | |
|---|---|---|
| Number of patients | Percentage of patients | |
| Placebo | 811 | 27 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 759 | 25.4 |
(NCT00144339)
Timeframe: Day 1 to 4 years
| Intervention | Participants (Number) | |
|---|---|---|
| Number of patients | Percentage of patients | |
| Placebo | 2049 | 68.2 |
| Tiotropium Bromide Inhalation Capsules 18 mcg | 2001 | 67 |
6 reviews available for theophylline and Disease Exacerbation
| Article | Year |
|---|---|
Doxofylline is not just another theophylline!
Topics: Animals; Asthma; Bronchodilator Agents; Disease Progression; Drug Interactions; Hospitalization; Hum | 2017 |
[Pregnancy and bronchial asthma].
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Bronchodilator A | 2014 |
Mechanisms and clinical consequences of untreated central sleep apnea in heart failure.
Topics: Brain; Cardiac Output; Comorbidity; Disease Progression; Electric Stimulation Therapy; Endothelium, | 2015 |
Can β2-adrenoceptor agonists, anticholinergic drugs, and theophylline contribute to the control of pulmonary inflammation and emphysema in COPD?
Topics: Adrenergic beta-2 Receptor Agonists; Animals; Bronchodilator Agents; Cholinergic Antagonists; Diseas | 2012 |
[New drug therapy of chronic obstructive pulmonary disease].
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Antidepressive Agents | 2003 |
[Acute exacerbations of chronic obstructive pulmonary disease: special reference to pathophysiology and management].
Topics: Adrenergic beta-Agonists; Anti-Inflammatory Agents; Cholinergic Antagonists; Disease Progression; Hu | 1999 |
5 trials available for theophylline and Disease Exacerbation
| Article | Year |
|---|---|
Impact of theophylline/corticosteroid combination therapy on sputum hydrogen sulfide levels in patients with COPD.
Topics: Adrenal Cortex Hormones; Biomarkers; Bronchodilator Agents; Disease Progression; Forced Expiratory V | 2014 |
Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial.
Topics: Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adult; Anti-Bacterial Age | 2015 |
The effect of active and passive household cigarette smoke exposure on pregnant women with asthma.
Topics: Administration, Inhalation; Administration, Oral; Adult; Asthma; Beclomethasone; Disease Progression | 2010 |
Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Aged; Bronchodilator Agents; Cholinergic Antagoni | 2010 |
Effect of obesity on clinical presentation and response to treatment in asthma.
Topics: Acetates; Adult; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Cyclopropanes; Cytokines; Dis | 2006 |
9 other studies available for theophylline and Disease Exacerbation
| Article | Year |
|---|---|
Doxofylline in acute exacerbation of chronic obstructive pulmonary disease.
Topics: Disease Progression; Humans; Pulmonary Disease, Chronic Obstructive; Theophylline | 2022 |
Severe Exacerbations of Systemic Capillary Leak Syndrome After COVID-19 Vaccination: A Case Series.
Topics: Aged; Capillary Leak Syndrome; Cardiovascular Agents; COVID-19; COVID-19 Vaccines; Disease Progressi | 2021 |
Cyclic AMP can promote APL progression and protect myeloid leukemia cells against anthracycline-induced apoptosis.
Topics: 1-Methyl-3-isobutylxanthine; Animals; Antibiotics, Antineoplastic; Apoptosis; bcl-Associated Death P | 2013 |
[Update on current care guidelines: Chronic obstructive pulmonary disease, diagnosis and treatment].
Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Anti-Bacterial Agents; Bronchodilator Agents; | 2010 |
Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery.
Topics: Adrenal Cortex Hormones; alpha 1-Antitrypsin; Aminopyridines; Anti-Bacterial Agents; Asthma; Benzami | 2012 |
Neuroendocrine lung carcinogenesis in hamsters is inhibited by green tea or theophylline while the development of adenocarcinomas is promoted: implications for chemoprevention in smokers.
Topics: Adenocarcinoma; Animals; Bronchodilator Agents; Cell Transformation, Neoplastic; Chemoprevention; Cr | 2004 |
[Treatment compliance in asthma: a Tunisian transversal study].
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Androstadienes; Anti-Asthmatic Agents; A | 2005 |
[COPD--how to deal with an acute exacerbation].
Topics: Acute Disease; Adrenal Cortex Hormones; Anti-Bacterial Agents; Bacterial Infections; Bronchodilator | 2006 |
Theophylline, pentostatin (Nipent), and chlorambucil: a dose-escalation study targeting intrinsic biologic resistance mechanisms in patients with relapsed lymphoproliferative disorders.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy | 2000 |